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Abstract  121 The Nordic region, comprised here primarily of Denmark, Estonia, Finland, 122 Iceland, Norway, and Sweden, has many of the characteristics necessary to 123 be at the forefront of genome-based precision medicine. These include 124 egalitarian and universal health-care, expertly-curated patient and 125 population registries, biobanks, large population-based prospective 126 cohorts linked to registries and biobanks, and a widely embraced sense of 127 social responsibility that motivates public engagement in biomedical 128 research. However, this can only be achieved through coordinated action 129 involving all actors of the healthcare sector. Now is an opportune time to 130 organize scientists in the Nordic region, together with other stakeholders 131 including patient representatives, governments, pharmaceutical 132 companies, academic institutions, and funding agencies, to initiate a Nordic 133 Precision Medicine Initiative. We present a roadmap for how this can be 134 done. The Initiative will facilitate research, clinical trials, and knowledge 135 transfer to meet regional and global health challenges.  136  137 Background 138 Complex disease is caused by environmental exposures perturbing 139 multiple biochemical pathways. Determining the impact of these exposures 140 on the individual patient, and the extent to which these can be mitigated by 141 therapy, are fundamental objectives of contemporary medicine. One of the 142 major goals is to tailor medicine to the patient, not only by understanding 143 the disease, but also by understanding the specific characteristics of the 144 person. Another important goal is to accurately determine a person’s risk 145 of developing disease, and to use this information to optimize the timing, 146 
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delivery and type of preventive action. Collectively, these goals represent 147 
precision medicine1: individual preventive and therapeutic interventions 148 incorporating a detailed understanding of human diversity.  149 Human diversity is determined by the joint effects of environmental 150 exposures and DNA sequence variation2. Genotyping millions of common 151 DNA variants in very large human populations has been made possible by 152 recent major technological advances. These technologies have been used to 153 discover and characterize many thousands of independent association 154 signals between common variants and disease traits. In general, common 155 single nucleotide polymorphisms (SNPs) individually confer relatively little 156 risk, but jointly, account for a substantial proportion of the overall 157 heritability of many complex disorders; for instance, in mental disorders, 158 the proportion of variance attributable to genome-wide SNPs (liability-159 scale SNP heritability) is between a third and a quarter of the overall 160 heritability3,4. Methods have been developed to use a large number of 161 sequence variants to construct what is often termed a polygenic risk score 162 for phenotypes5. Polygenic risk scores can be useful in assessing both 163 relative and absolute risks of diseases. The frequencies and effects of 164 common variants tend to be similar in most ethnic groups with some 165 exceptions. The most recent breakthroughs in understanding the 166 relationships between human DNA sequence variation and phenotypic 167 diversity have been made possible by the development of technologies for 168 sequencing whole genomes or whole exomes in very large populations; this 169 in turn has identified rare risk variants, and expanded the catalogue of 170 verified polymorphic genomic regions related to disease6,7. Many of the 171 recently discovered rare variants cluster in the coding part of genes that 172 confer high risk of various diseases8. It is, however, important to remember 173 that the rare variants have arisen recently and tend to be population-, or 174 
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even family-, specific. Nevertheless, even de novo mutations, affecting the 175 probands but not their parents, have proven relevant for public health9,10. 176 Although these major technical advances in human genetics have been a 177 driving force in the evolution of precision medicine, there are many 178 practical obstacles hindering the implementation of these technologies at 179 scale. We argue that the Nordic countries (Fig. 1) offer a priviledged 180 environment to negotiate these obstacles making it likely that, with a well-181 functioning organizational structure and adequate funding, the Nordic 182 countries will likely play a very significant role in precision medicine over 183 the coming years, at least as it relates to the diseases common within the 184 region. Indeed, given the region’s unique resources, we feel obligated to 185 ensure that this possibility is realized.  186 Although major progress has been made in disease genomics, further 187 characterization will require very large prospective cohorts with 188 harmonized genetic and phenotypic data, yet such datasets are uncommon 189 in most parts of the world. Over recent decades, the Nordic countries have 190 individually collected very large, carefully phenotyped, prospective 191 cohorts, often for the sake of disease monitoring and surveillance. These 192 cohorts and registries contain data from the majority of Nordic citizens, 193 following many of them throughout parts of the life-course; data are often 194 collected through primary care clinics, hospitals, and post-mortems. This 195 process has resulted in the availability of datasets comprising some 27 196 million Nordic citizens (Fig. 1), many of whom have undergone repeated 197 sampling over many decades. Notably, a considerable amount of today’s 198 knowledge on the epidemiology of human disease is based on research 199 from Nordic cohorts and registries (Supplementary Table 1). 200 
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The Nordic countries include Denmark, Finland, Iceland, Norway, and 201 Sweden, with their associated territories (Greenland, the Faroe Islands, and 202 the Åland Islands). The 27 million people of the Nordic countries are 203 ancestrally mainly Scandinavian or Finnish, with Greenlandic Inuit (around 204 56,000) and the Sami (50-80,000) as indigenous peoples. Estonians share 205 language and historical roots with the Finns and identify very closely with 206 Nordic culture. Furthermore, with its well-established national biobank, 207 Estonia has been an active partner in the Nordic Biobank Network. Despite 208 the fact that the region for centuries has had immigration from 209 neighboring, continental countries, and more recently from elsewhere, 210 immigrants still comprise only a minor proportion of the Nordic 211 population. In 2012 for instance, 10.9%, 7.9%, and 14.9% of the 212 Norwegian, Danish, and Swedish populations were immigrants, 213 respectively (Statistics Norway). The Nordic countries have much in 214 common in their way of life, history, social structures, and languages. These 215 countries do not form a truly united political entity, but co-operate closely 216 on many levels, including within the Nordic Council.  217 
 218 Access to unique data needed to apply precision medicine 219 One of the assets needed for the implementation of precision medicine is 220 collections of data on individual phenotypes and genotypes that allow 221 detailed studies of the causal effects of genetic variants in disease. Such 222 datasets can be used for the crucial replication of published genetic 223 associations with disease and other relevant phenotypes, as well as for 224 determining population-specific frequencies and the extent to which 225 specific variants impact disease (effect size or predictive accuracy). These 226 datasets are, however, of greatest value for i) discovering genomic variants 227 
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that pinpoint druggable pathways, ii) aiding in the reclassification of 228 disease diagnoses (to generate new taxonomies that can be treated more 229 effectively), and iii) facilitating the stratification of populations based on 230 risk factor susceptibility or therapuetic response (to optimize prevention 231 or treatment), each of which are core features of precision medicine.  232 Although today there is no truly pan-Nordic database on phenotypes and 233 genotypes, the required components exist. These include: (a) a long history 234 of integrated healthcare, patient registries and biobanks, with existing 235 assets of biological samples, patient records, and longitudinal follow-up; 236 (b) population characteristics such as founder effects and stable, traditional 237 societies with homogeneous environmental exposures; (c) strong public 238 trust based on a history of social welfare and commitment to research for 239 the public good; and (d) access to technology and expertise for generating, 240 managing, storing and interpreting genomic and clinical data 241 (Supplementary Table 2). What remains is to bring together the wealth of 242 data and biomaterials under a common framework, and to make this 243 accessible to the research community through federated data-access 244 models. 245 No other countries currently have access to population-based registries of 246 comparable size and with similar quality and detail of clinical information 247 as those of the Nordic nations (Box 1). The unique features of this Nordic 248 resource include complete nationwide social and health registers from 249 about 1950 onwards, the world´s largest health studies with detailed 250 phenotypes, biological samples, follow-up of 30-50 years, hospital 251 diagnoses as well as prescription and treatment registries, including all 252 inpatients and outpatients for all hospitals during the past decades, and 253 newborn screening programs of live births with samples stored since the 254 early 1980s. There are population-based biorepositories and data from at 255 
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least 8-10 million individuals available for research in the Nordic countries 256 today.    257 Regarding the secure storage and use of data and the challenge of utilizing 258 data while protecting the data donor's privacy, the Nordic region has 259 advantages due to its traditions of equality and a strong public sector. The 260 citizens generally commit to studies with broad consent. In all Nordic 261 countries, there is an overall positive attitude toward health research, 262 including genetic studies11. There is a healthy balance between privacy 263 regulations and willingness to share data for research. New European 264 Union regulations may, however, create new challenges (Box 2). As the 265 European General Data Protection Regulation (GDPR) came into effect in 266 May 2018, its full consequences remain unknown. There are, however, 267 clear ways in which GDPR expectations can be fulfilled. Implied consent is 268 sufficient for data that are not sensitive, while analysis of sensitive data 269 requires opt-in consents specific for each research question addressed with 270 the data.  271 deCODE genetics in Iceland and through its collaboration elsewhere in the 272 Nordic region has been at the forefront of human genomic research for two 273 decades (Supplementary Table 1). This engagement corresponds with the 274 generation of extensive genotype data from SNP arrays for some 650,000 275 Nordic participants. Whole exome or genome sequence data from over 276 95,000 Nordic participants have also been generated. deCODE genetics has 277 genotyped half of the Icelandic nation and performed whole genome 278 sequencing on ten percent of it12. In addition to work done in the Nordic 279 countries13, recent significant contributions to human genetics coming 280 from the USA have been made through the use of clinical material, 281 registers, cohorts, and biobanks in the Nordic countries (Supplementary 282 
Table 1)14,15. A pilot project on colorectal cancer supported by the Nordic 283 
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Council of Ministers has connected biobanks and registries in all Nordic 284 countries, including transfer of personal data between Nordic countries as 285 well as joint genotyping and whole genome sequencing of biospecimens 286 from several Nordic countries, demonstrating that the infrastructure and 287 regulations allow considering the Nordic countries as a single scientific 288 region (NordForsk).  289 The Nordic countries have also been at the forefront of epidemiological 290 studies linking environmental exposures to disease outcomes. These 291 studies have identified the diversity in exposure to important external 292 determinants of disease. Until now, these have been largely independent of 293 genetic information, and genetic association studies have mostly been 294 conducted independently of known environmental risk factors, despite 295 many large-scale epidemiological studies in the Nordic countries during the 296 past 50 years. Whilst the origins of precision medicine have come from 297 population genetics research, the successful implementation of precision 298 medicine to tackle common complex disease will almost certainly require 299 consideration of the joint effects of genes and environment, as lifestyle has 300 a major influence on most common diseases. Recently, DNA has been 301 extracted, genotyped or sequenced in many of these outstanding Nordic 302 cohorts, enabling adequately powered pioneer studies uncovering the 303 interplay of the environment and genetics. 304 A special feature of the Nordic countries is the existence of multiple genetic 305 isolates, some of which are contained within the large registers and 306 biobanks. This unique resource has facilitated the discovery of variants that 307 are private to specific population isolates or families. An example is 308 detection of a rare loss-of-function (LoF) variant in the SLC30A8 gene that 309 is protective for type 2 diabetes and enriched in the Botnia region14. To 310 explore the underlying mechanisms, we were able to go back to the families 311 
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carrying the LoF mutation and by sequencing additional family members, 312 increased the number of mutation carriers 3-fold. We then selectively 313 recruited participants by genotype for additional metabolic studies to 314 pinpoint the mechanisms for protection. Although Finland is not technically 315 an isolate, its history – small founder population, evolutionary bottleneck 316 and then rapid expansion – makes it ideal for identifying rare mutations.  317 Several initiatives that pave the way for a Nordic precision initiative are 318 now underway in individual countries: The Danish government and 319 municipal authorities have recently launched a national project in precision 320 medicine for the use of genetic analysis technologies in the prevention and 321 treatment of many diseases. Novo Nordisk Foundation has recently 322 announced its support this initiative with over 900 mill DKK (approx. 137 323 mill USD). In Finland, major changes in the legal framework are currently 324 undergoing parliament hearings: National registers, genome, and biobank 325 legislation will be reorganized to improve the secondary use of health data 326 in research and development. The Research Council of Norway, as well as 327 major universities and university hospitals, and the Norwegian Institute of 328 Public Health, are increasingly supporting projects on precision medicine, 329 and the legal framework is becoming more positive towards genetic studies 330 utilizing population registers and biobanks. The Swedish government has 331 commissioned the Swedish Research Council to support national 332 infrastructure for register-based research, including clinical registers. 333 Work is ongoing to create a single national entry point for research using 334 registers, cohorts and biobanks. The NordForsk funding agency is further 335 actively supporting development of mechanisms for secure sharing of 336 person-sensitive data across the Nordic countries through Tryggve, and the 337 Nordic ELIXIR nodes are similarly enabling secure data exchange through 338 participation in national European Phenome-Genome repositories. 339 
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SNP array studies have shown a close correspondence between genetic and 340 geographic distances in Europe and that the geographical map of Europe 341 naturally arises as an efficient two-dimensional summary of genetic 342 variation in Europeans16,17. Their descent can genetically, and hence 343 geographically, be distinguished by drawing a line from the north to the 344 south-east (northern Europe to the Balkans), with another east-west axis 345 across Europe. Y-chromosome studies show three large haplogroups that 346 account for most of Europe's patrilineal descent. Nordic populations 347 overlap considerably, particularly in major cities and neighboring regions, 348 but differ from other European populations in their genetic substructure, 349 with Finns being especially distinct, to the extent that they are essentially a 350 genetic isolate18. This is also reflected in the language groups 351 (Supplementary Fig. 1). Hence, in addition to the wisdom of working with 352 the biobanks in the individual Nordic populations and the ability to link 353 them to population registries on healthcare information and other relevant 354 demographic data, the shared ancestry of the Nordic peoples that is 355 reflected in overlap of genomic sequences makes them ideal partners in 356 genetic research and in the implementation of precision medicine 357 (Supplementary Fig. 2). 358  359 Healthcare with universal access and societal acceptance 360 Another asset necessary for early implementation of precision  medicine is 361 government-funded healthcare systems with excellent records and 362 universal access that are focused on longterm benefits to society rather 363 than shortterm profit. An additional asset is having societies that are 364 committed to protecting the rights of individuals to privacy while 365 
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recognizing the importance of using healthcare information for discoveries 366 that improve health and care. 367 A number of factors predict that precision medicine may be implemented 368 across the region without worsening health disparities. Indeed, we argue 369 that this strategy is a necessary extension of a number of economic and 370 cultural specialities of the region. The Nordic countries rank at the top in a 371 range of metrics of national economic performance, including education, 372 digitalization, economic competitiveness, civil liberties, quality of life, and 373 human development19. Together, the economies of the Nordic countries 374 have one of the best macroeconomic performances in the world, and are 375 leaders in sustainable development. The Nordic countries also share many 376 aspects of their economic systems and social structures: market economy is 377 combined with relatively strong labor unions and a well-developed public 378 welfare sector20. There is a high degree of income distribution and 379 relatively little social unrest. Individual rights are secured legally and have 380 an increasingly strong influence on the health care systems. In general, 381 inhabitants of the Nordic countries are positive towards research and 382 frequently consent to genetic research with a wide scope both as 383 participants in disease-specific cohorts and population-based general 384 health surveys. The Nordic countries all have single payer healthcare 385 systems with good access and quality of services. Our precision medicine 386 strategy hence appears as a natural extension of economic and cultural 387 specificities of the region. 388  389 In spite of these qualities of the Nordic societies, extensive coordination 390 and ambitious funding strategies are required to achieve the necessary 391 societal support to enable the implementation of precision medicine. 392 Efforts to introduce population genomics in the Nordic countries will rely 393 
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on a combination of public and foundation funds, as well as investments 394 from biotechnology and pharmaceutical industries. This can induce 395 concerns about the protection of the rights and privacy of citizens, which 396 will need to be adequately addressed if public support is to be maintained. 397 The European GDPR offers the opportunity for the Nordic countries to align 398 processes for personal data used in research. A second issue is the need to 399 find solutions to how the value that is generated in the international 400 private sector using samples and data from the Nordic region shall be 401 returned to the nations and citizens who funded and generated these 402 resources. A third good example of the opportunities and challenges ahead 403 is provided by the story of the BRCA2 mutation in Iceland. Work done at 404 deCODE genetics has brought insight into the whole genomes of most of the 405 nation. Hence, all BRCA2 mutation carriers in Iceland could in theory be 406 identified in silico and offered interventions that mitigate the cancer risk 407 conferred by the mutation21,22. This would be an excellent example of how 408 precision medicine can contribute substantially to public health. This has, 409 however, not been done yet, because the Icelandic society is still debating 410 how to approach the mutation carriers with this clinically critical 411 information. There are people who are deeply concerned about the right of 412 the carriers not to know about their genetic risk. Shall the participants in 413 research studies always have the right to learn the results, even if the 414 medical consequences of the genetic discovery are not yet fully 415 understood? As this situation illustrates, the obstacles to the 416 implementation of precision medicine are not only financial, technical and 417 scientific, but also societal and ethical. We believe that the people of the 418 Nordic region are ready to tackle these challenges and offer a positive 419 example for the rest of the world11. 420 
 421 
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A roadmap for the way forward 422 
Recently, the Nordic Society for Human Genetics and Precision Medicine 423 was formed and launched a roadmap for the way forward (Box 3). The 424 Society was created in order to: (a) accelerate discovery of disease 425 susceptibility genes and genes protecting from disease through integrated 426 analyses using multiple large-scale datasets and a range of experimental 427 designs; (b) translate these findings so that they can be used for precision 428 medicine to improve public health; (c) and uphold and promote the highest 429 legal, regulatory, social, and ethical standards.    430 The Society will also be a vehicle to engage the many constituencies of 431 precision medicine, ranging from research and clinical geneticists to data 432 scientists and legal experts. It will also allow for the communication of 433 accurate, up-to-date information to policymakers, research funders, and, 434 most importantly, the public. 435 We believe our initiative will accelerate research, clinical trials, and 436 transmission of knowledge to meet numerous local, regional, and global 437 health challenges, taking advantage of the unique Nordic health-care 438 system, patient and population registries and biobanks, as well as the social 439 responsibility that has motivated public engagement in biomedical 440 research.  441  442 URLs 443 Danish strategy for personalized medicine, http://www.sum.dk/English.aspx; 444 deCODE genetics, https://en.wikipedia.org/wiki/DeCODE_genetics; 445 European Commission, Joint Research Center,  http://data.europa.eu/89h/jrc-446 
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Figure legend 559 
Figure 1: The Nordic countries, a geographical and cultural region in 560 
Northern Europe and the north Atlantic sea.  561 The Nordic region has around 27 million inhabitants. The population 562 number is shown for Iceland, the kingdoms of Denmark, Norway, and 563 Sweden, and the republic of Finland, and associated territories. These are 564 Greenland and Faroe Islands (ruled by Denmark), Åland Islands (ruled by 565 Finland), and Svalbard (ruled by Norway). Estonia is often associated with 566 the Nordic countries as well. Population density as of 2015 was obtained 567 from the Global Human Settlement project and displayed in shades of grey 568 (Supplementary Note; European Commission, Joint Research Centre, 569 Columbia University, NYC, NY). Abbreviations: k, thousand; mil, million; 570 inhab, inhabitant. 571 
 572 
  573 
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Boxes 574  575 
Box 1: Selected examples of population-based cohorts, biobanks and registers in the Nordic region  Denmark The Danish National Biobank at Statens Serum Institut (www.ssi.dk) contains eight million specimens increasing by 0.5 million annually. Most are serum, plasma and DNA, although there also are spinal fluids, faeces and urine. Eleven robots are effectively performing pipetting, DNA purification, biomarker analysis, and storage. Detailed phenotypic data can be obtained via a linkage to national registers. The National Biobank Register (www.nationalbiobank.dk) includes 22 million specimens from 5.4 million persons in Danish biobanks. Combining data with register information allows searching for diagnosis, age, sex and other variables as well as specific searches that e.g. will identify specimens taken at specific time points before, at, or after a certain diagnosis. Participation and use is free of charge. Bio- and Genome Bank Denmark (www.regioner.dk/rbgben) is the entry to biological material at all hospitals. The material is professionally collected, nationally registered and regionally stored in five hospitals. Pathological material is stored locally for clinical use. Phenotypic data can be obtained via linkage to registers and clinical databases. The Danish Neonatal Screening Biobank includes filter blood spots from two million subjects, almost all that are born since 1982. iPSYCH (www.ipsych.au.dk) is the largest study utilizing these samples, including GWAS of 80,000 individuals, of which 50,000 suffer from mental disorders, integrating genomic and national register data.   The Danish National Birth Cohort (www.ssi.dk) contains holds questionnaire data from pregnancy (100,000) and the offspring at six and 18 months as well as seven and 11-year follow-ups. Biological specimens have been collected twice during pregnancy together with cord blood (Danish National Biobank).  Estonia The Estonian Biobank is population-based (www.biobank.ee) including medical history and current health status as well as extra data from psychiatric patients. All samples (155,000) have been genotyped (SNP arrays); while exome sequencing has been done on 2,500 and whole 
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genome sequence on 2,500 samples. The biobank can be linked with national health registries and hospital databases.  Finland The National Institute of Health and Welfare (THL) hosts the majority of large epidemiological and disease specific cohorts (e.g. Finrisk, Health2000, Twins, Botnia, Migraine, GeneRisk) that contain blood samples from 200,000 individuals (www.thl.fi/biobank) of all ages. These include questionnaire, genomic, and biochemical data and link to National Health Register data (EHR) providing decades of disease follow-up data. All university hospitals have established biobanks linking sample data with EHR and EMR data. Hospital biobanks host tissue samples from almost 3 million participants, collected earlier as part of routine diagnostics and have recently been transferred to biobanks. The hospital biobanks as well as the Blood Service Biobank have recently collected prospective samples from 120,000 participants and continue rapidly expanding their collections. The rapid expansion is due Finnish Biobanks partnering with the public-private FinnGen project aiming to collect GWAs and national health register data from 500,000 participants by 2022 (https://www.finngen.fi/). The FinnGen research project has been a major facilitator for development of national biobanking and the accumulated genome data of FinnGen – currently 145 000 – is foreseen to serve as a major basis for GWAS and PheWAS analyses towards development of personalized medicine.  For biobanks, the newly produced genome data will further enrich the EHR data with symptom-level information, pathology and biochemical data thus building more possibilities for excellent science and development. All biobanks are networked by BBMRI.fi and have harmonized broad consents and practices. Iceland deCODE genetics (www.decode.com) has gathered genotypic and medical data from over 160,000 participants, well over half of the adult population. Using Iceland’s uniquely comprehensive genealogical records, deCODE has also a genealogy database covering the entire present day population stretching back to the founding of the country more than 1,000 years ago. The combination of size of the population, the participation of so many people in the discovery work, the genealogies, and high quality universal healthcare have made possible very large-scale studies of virtually any common disease. At the same time, deCODE´s work has minimized the selection bias that confronts research in larger, more stratified populations, enabling to impute or predict genotypes using the genealogies, multiplying many-fold the 
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amount of data that can derive from genotyping and sequencing.  Norway The Norwegian Mother and Child Cohort Study (MoBa) is a pregnancy cohort (114,500 children, 95,000 mothers, 75,000 fathers) recruited 1999-2009 (www.fhi.no/MoBa). Information on health and exposures are collected from questionnaires during pregnancy and regularly after birth, and by linkage to registries. Biomaterials were collected from fathers and mothers at pregnancy week 17 and after birth, and from umbilical veins. DNA has been extracted. 25,000 triads have been genotyped (SNP arrays). Many outcome registries have been linked to the cohort. The Health Survey of Northern Trøndelag (HUNT) contains medical histories and specimens (120,000) from a homogeneous population collected over 30 years (www.hunt.no). Three surveys include information on health-related lifestyle, prevalence and incidence of diseases, health determinants, and associations between disease phenotypes and genotypes. 70,000 samples have been genotyped (SNP arrays). Data can be linked to national health registries.  The Tromsø Study is prospective and population-based with six repeated health surveys after 1974 (www.tromsoundersokelsen.no) including questionnaire data, DNA, serum, and clinical measurements. 40,000 subjects attended at least once, and 15,000 in three surveys or more. In addition to national quality controlled disease registries, the study holds a validated endpoint registry of many well-defined diseases. The Hordaland Health Studies (husk-en.b.uib.no) were conducted in 1992/93 (The Homocysteine study) and in 1997/99 (HUSK). The main focus is cardiovascular disease, cancer, osteoporosis, anxiety and depression. Some 36,000 residents of Hordaland county participated; 18,000 in 1992/93 and 26,000 in 1997/99. About 7,000 of those who participated in the 1992/93 survey also participated in 1997/99. 
 Sweden The Genomic Aggregation Project in Sweden (GAPS) has around 30 Swedish cohorts within which existing detailed genetic and phenotypic data is available (170,000). Within these cohorts exists tens of thousands of additional data-points against which blood samples are stored, from which DNA will be extracted for future genotyping and sequencing. The cohorts already genotyped include the Malmö Diet and Cancer cohort (28,000) in southern Sweden, the Breast Cancer Studies 
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cohort (30,000) in the central Sweden, the GLACIER Study (20,000) in northern Sweden, and multiple case-control and cohort studies of severe psychiatric disorders (63,000). Aside from disease record linkage, cohorts in Sweden are frequently linked to the drug registry and demographic databases (allowing genealogies dating back to the 1700s to be linked with genetic and phenotypic data).  ANDIS is a large and well-phenotyped study comprising all new subjects with diabetes in Skåne, a complete-capture case series of >15,000 patients with diabetes, from which samples have been genotyped and linked to a range of cross-sectional and prospective registry databases. 
Text box 2: The European Union’s General Data Protection Regulation and the Nordic Countries  The General Data Protection Regulation (GDPR, Regulation (EU) 2016/679) of May 25, 2018 replaced the Data Protection Directive (officially Directive 95/46/EC on the protection of individuals with regard to the processing of personal data and on the free movement of such data). The European Commission's (EC) objectives with this new legislation included the harmonization of 27 national data protection regulations into one unified regulation, the improvement of corporate data transfer rules outside the European Union (EU), and the improvement of user control over personal identifying data. The proposed new EU data protection regime thus extends the scope of the EU data protection law to all foreign companies processing data of EU residents. It provides for a harmonization of the data protection regulations throughout the EU, thereby making it easier for non-European companies to comply with these regulations; however, this comes at the cost of a strict data protection compliance regime with severe economic penalties.  The GDPR preserves the equilibrium between the necessity of effectively protecting the subject’s rights in a digitalised and globalized world while allowing the processing of personal data, including sensitive data, for scientific research. It reinforces cooperation duties and transparency between the actors of the processing, internally and with regard to the supervisory authorities, which should create a more integrated EU data protection system and diminish some useless administrative costs by decentralising elements of the data protection governance towards data controllers and processors. Whilst the GDPR adopts new specific provisions to ensure adapted data protection in research, the field remains widely regulated at national level, in particular, regarding the application of research participants’ rights, 
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which some could regret. However, the GDPR has the merit to set up clearer rules that will positively serve the research practices notably regarding consent, regarding the rules for reusing personal data for another purpose, assessing the risks of data processing in the context of data protection impact assessment, adopting accountable management system of processing operations and building or reinforcing internal data protection competencies with the data protection officer. In addition, for the first time, the GDPR refers to the respect of ethical standards as being part of the lawfulness of the processing in research, what must be welcomed as an effort for sector-specific consistency. Finally, the GDPR opens new possibilities for structuring data sharing in scientific research with measures encouraging self-regulation development. 
 576 
 577 
Box 3: Roadmap for the precision medicine initiative in the Nordic region  Develop the Nordic Society for Human Genetics and Precision Medicine, among whose tasks will be to: 
• Organize biannual large open scientific meetings 
• Organize a series of workshops targeted to the constituencies of precision medicine, e.g., research geneticists, clinical geneticists, data scientists, legal scholars  
• Write a white paper that summarizes the major needs 
• Develop web-based resources, including a news feed, continuous updated overview of available cohorts, registers, and biobanks, as well as linked genomics and metabolomics information  Engage with important constituencies 
• Policymakers 
• The public 
• Other organizations in this sphere
• Interact with funding partners 
• NordForsk 
• National research councils 
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Schizophrenia, Type,2,diabetes, Lipid,Disorders, Glioblastoma, Alzheimer’s,
disease,
Melanoma, All,
! n"(%)" n"(%)" n"(%)"! n"(%)! n"(%)! n"(%)! n"(%)! n"(%)"
Nordic, 93,510!" (48%)" 7,051" (40%)" 9,817! (35%)! 42,094! (22%)" 4,067! (13%)" 6,094! (8%)" 994" (2%)" 163,627! (28%)"
USA, 7,018!! (4%)! 2,281! (13%)" 3,767! (13%)! 1,586! (1%)" 18,914! (59%)" 28,550! (39%)" 8,951! (21%)! 71,067! (12%)"
UK, 30,122!! (15%)! 4,407! (25%)" 7,120! (25%)! 22,746! (12%)" 4,204! (13%)" 12,010! (16%)" 12,872! (30%)! 93,481! (16%)"
Other, 63,777!! (33%)! 3,970! (22%)" 7,646! (27%)! 122,151! (65%)" 4,769! (15%)" 27,089! (37%)" 20,390! (47%)! 249,792! (43%)"
Total, 194,427! ! 17,709! ! 28,350! ! 188,577! ! 31,954! ! 73,743! ! 43,207! ! 577,967! !





































Supplementary! Figure! 2:! Common! variant! sharing! shows! similarity! of! Nordic!
populations!
A!comparison!of!22,500!Icelanders!typed!for!the!Illumina!Omni!Express!SNP!chip!against!




IBD! between! the! Icelanders! and! each! of! the! 19! populations,! with! 95%! confidence!










the! link!below.! In!short,! the!world!map!using!the!Mollweide!projection!was!plotted! in!
light!yellow!over!a!light!blue!background.!The!countries!of!the!Nordic!region,!composed!





a! resolution! of! 1! km! (European! Commission,! Joint! Research! Centre! [JRC];! Columbia!
University,!Center!for!International!Earth!Science!Information!Network!=!CIESIN![2015]:!





along!with! the!number!of! inhabitants!was!annotated! for!each! country!and!associated!








The!Nordic! countries!and!associated! territories!were! colored!according! to! the!official!
language.! The! Sami! language! was! annotated! with! horizontal! segments.! Capitals! and!
major!cities!were!annotated!with!points!and!names!using!their!latitude!and!longitude!as!
obtained!from!latlong.net.!North!Germanic!languages!were!annotated!using!a!gradient!of!
blue,!Finno=Ugric!languages!using!a!red!to!yellow!gradient,!and!Inuit!as!part!of!Eskimo=
Aleut!languages!in!green.!
!
URLs:!!
Script:!https://github.com/mvaudel/Nordic=maps!
Global!Human!Settlement!project:!https://ghsl.jrc.ec.europa.eu/ghs_pop.php!
European!Commission,!Joint!Research!Centre!(JRC):!http://data.europa.eu/89h/jrc=ghsl=
ghs_pop_gpw4_globe_r2015a)!
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